Automation in the Molecular Diagnostics Market by Product Type (Consumables & Reagents, Instruments, Software & Services), Technology (Microarrays, Ngs, Pcr), Automation Level, Application, End User - Global Forecast 2025-2032
Description
The Automation in the Molecular Diagnostics Market was valued at USD 13.54 billion in 2024 and is projected to grow to USD 15.78 billion in 2025, with a CAGR of 16.65%, reaching USD 46.42 billion by 2032.
A comprehensive orientation to the technological, operational, and commercial forces reshaping automation across molecular diagnostics laboratories and service providers
The molecular diagnostics sector is in the midst of a structural and technological transition driven by the convergence of automation, genomics, and data-centric workflows. Laboratories face mounting pressures to increase throughput, shorten turnaround times, and maintain rigorous quality standards while managing constrained budgets and an evolving regulatory environment. Concurrently, advances in sample handling, assay chemistry, and integrated informatics have created a pathway toward more repeatable, scalable laboratory operations that reduce error rates and enable broader clinical adoption of complex tests.
This report frames automation not as a single technology but as an orchestrated set of capabilities that span consumables, instrumentation, software, and services. As automation spreads beyond centralized reference labs into hospital laboratories and specialized clinical settings, stakeholders must rethink procurement, validation, and operational models. Early adopters are demonstrating measurable gains in workflow efficiency and capacity, and the ripple effects extend to payers, clinicians, and patients through faster diagnoses and more reliable results.
Given these dynamics, strategic decision-makers require a synthesis of technical, operational, and commercial perspectives. This executive summary synthesizes those perspectives to inform capital allocation, partnership strategies, and product development priorities, thereby equipping leaders to navigate the near-term opportunities and operational challenges presented by automation in molecular diagnostics.
Exploring how modular platforms, digital integration, and evolving commercial models are fundamentally transforming laboratory automation and molecular testing operations
Over the last several years, the landscape of molecular diagnostics has shifted from fragmented point solutions toward integrated automation platforms and ecosystem partnerships. Laboratories and manufacturers alike are prioritizing modularity in design to enable incremental upgrades and cross-platform compatibility, which eases integration of next-generation sequencing, PCR, and microarray workflows. This shift reflects a broader industry movement toward platform-based thinking, where instruments, consumables, and software co-evolve to deliver predictable end-to-end performance.
At the same time, digital transformation continues to accelerate, with data analysis software, integration services, and managed services gaining prominence as differentiators. Interoperability and standards-based data exchange now influence procurement decisions as strongly as instrument throughput. Decentralization of testing capacity, driven by demand for rapid results and the need to reduce sample transport times, is prompting investments in walkaway automation that can operate in lower-acuity settings.
These transformative shifts are producing new commercial models. Vendors are expanding beyond hardware sales to provide recurring-revenue offerings centered on consumables, data analytics subscriptions, and service contracts. As a result, strategic partnerships across diagnostic developers, laboratory networks, and software providers are becoming essential to scaling complex molecular tests and delivering consistent clinical value.
Assessing the supply chain recalibrations, procurement strategies, and regulatory validation pressures resulting from recent tariff changes affecting molecular diagnostics components and instruments
The introduction of new tariffs affecting components and finished diagnostics products has layered additional complexity onto an already intricate global supply chain. Increased duties on certain imported instruments and reagents elevate the total landed cost for laboratories and distributors, prompting procurement teams to reassess sourcing strategies and total cost of ownership calculations. In response, some manufacturers have accelerated dual-sourcing initiatives and re-evaluated production footprints to mitigate exposure to region-specific levies.
Consequently, buyers are navigating a trade-off between near-term price pressures and longer-term supply assurance. Procurement teams are increasingly prioritizing suppliers that can demonstrate geographic diversification, transparent cost structures, and contingency plans for capacity constraints. Tariff-driven cost increases have also sharpened focus on consumable lifecycle costs and instrument utilization, as laboratories seek to protect operating margins without compromising diagnostic quality.
Regulatory considerations further complicate the environment, as changes in material origin can trigger additional validation work and documentation. In short, the tariff landscape has prompted industry participants to strengthen supply chain resilience, renegotiate contracts with a focus on total cost and service levels, and accelerate investments in local manufacturing where feasible to reduce dependency on cross-border flows.
Understanding how product, end-user, technology, automation level, and application segmentations together dictate adoption pathways and commercial priorities across molecular diagnostics
A nuanced view of segmentation clarifies where automation investments yield the greatest operational and commercial returns. When examined by product type, consumables and reagents-spanning microarray chips, NGS library prep kits, and PCR kits-often represent the recurring revenue engine that supports platform economics, while instrument categories such as microarray systems, NGS instruments, and PCR instruments command capital investment and determine throughput capacity. Software and services, including data analysis software, integration services, and managed services, serve as force multipliers that unlock instrument value through improved data handling and laboratory workflow orchestration.
From the end-user perspective, clinical laboratories and hospital laboratories place a premium on automation solutions that reduce hands-on time and accelerate turnaround for actionable results, whereas pharmaceutical and biotechnology companies prioritize high-throughput, reproducible workflows for discovery and early-phase development. Reference laboratories and research laboratories have distinct throughput and customization requirements, influencing the balance between standardized automated solutions and flexible semi-automated or walkaway approaches.
Technology segmentation highlights divergent adoption patterns across microarrays, NGS, and PCR. PCR remains indispensable for rapid, targeted testing, whereas NGS drives complex genomic profiling and increasingly benefits from automated library preparation and integrated informatics. Microarrays occupy niches where cost-effective multiplexing is required. Automation level is also a key determinant of procurement decisions: fully automated systems enable high-throughput, standardized operations; semi-automated systems offer flexibility for variable workloads; and walkaway automation lowers the skill threshold for decentralized testing environments. Application areas such as cardiovascular disease, genetic testing, infectious disease, oncology, and women's health present distinct assay validation needs and reimbursement contexts that shape product roadmaps and commercial strategies.
Analyzing distinct regional drivers and procurement realities in the Americas, Europe Middle East & Africa, and Asia-Pacific that shape automation adoption and commercial strategies
Regional dynamics exert a strong influence on how automation strategies are prioritized and executed. In the Americas, sizable reference laboratory networks and a relatively mature reimbursement environment encourage investments in high-throughput automated platforms, while clinical and hospital laboratories seek solutions that integrate seamlessly with existing LIS and EMR infrastructure. In contrast, Europe, Middle East & Africa displays a heterogeneous landscape where regulatory harmonization efforts and national procurement practices can accelerate uptake in certain markets while creating access barriers in others.
Asia-Pacific is characterized by rapid capacity expansion, strong government-driven diagnostic initiatives, and a diverse mix of centralized and decentralized laboratory models. Local manufacturing and supplier ecosystems in parts of the region have begun to reduce lead times and provide alternative sourcing options, which impacts procurement choices elsewhere. Across all regions, data interoperability, workforce skills, and capital allocation rhythms differ materially, influencing how vendors design deployment plans and after-sales support.
Taken together, these geographic distinctions underscore the need for differentiated commercialization strategies that reflect local regulatory requirements, supply chain realities, and customer preferences. Vendors and laboratory operators that align product configurations, training programs, and financing models with regional realities will navigate adoption barriers with greater agility.
Identifying corporate strategies, partnership models, and aftermarket services that industry participants are deploying to secure competitive advantage in automated molecular diagnostics
Competitive behavior in the sector reflects an intersection of product innovation, service orientation, and ecosystem building. Leading organizations are investing in vertically integrated platforms that combine instruments, consumables, and software to lock in recurring revenue streams and to simplify customer procurement. Others are pursuing a platform-agnostic approach that emphasizes software and services, enabling interoperability across multiple instrument vendors and positioning the company as a neutral integrator for complex laboratory estates.
Partnerships and co-development arrangements with assay developers, clinical laboratories, and academic centers are increasingly common, allowing companies to accelerate time-to-validation and expand test menus. Aftermarket strategies that include managed services, training, and performance-based contracts are being used to deepen customer relationships and to smooth revenue volatility associated with capital sales. In addition, supply chain resilience and regional manufacturing footprints have become strategic differentiators as organizations seek to mitigate tariff exposure and shorten lead times.
Companies that balance technological leadership with robust service offerings and transparent commercial models tend to win long-term contracts, while those that neglect integration, data analytics, or post-sale support face adoption friction. Overall, corporate strategies that emphasize modular innovation, flexible commercial terms, and collaborative partnerships position firms to capture a widening set of automation-driven opportunities within molecular diagnostics.
Actionable strategic and operational steps for manufacturers, laboratory operators, and policymakers to accelerate scalable, resilient automation adoption across diagnostics workflows
Leaders should adopt a pragmatic approach that aligns technology investments with clinical and operational objectives. First, prioritize modular automation platforms that enable phased adoption; this reduces validation burdens and allows organizations to scale capacity in line with demand. Second, diversify supply chains and establish contingency plans that include alternate suppliers and, where feasible, regional manufacturing partners to mitigate tariff and logistics risks.
Third, invest in software and integration capabilities to maximize instrument utilization and to reduce manual touchpoints. This includes prioritizing standards-based data exchange and investing in analytics tools that translate raw data into actionable clinical insights. Fourth, engage early with regulatory and reimbursement stakeholders to define evidence generation strategies that support test adoption and favorable coverage decisions. Fifth, expand service offerings such as managed services and training programs to address workforce constraints and to improve uptime and reliability.
Finally, pursue collaborative partnerships with clinical laboratories, assay developers, and healthcare systems to co-develop and validate workflows. These partnerships accelerate real-world adoption and create feedback loops that inform product roadmaps. Implementing these recommendations will strengthen resilience, accelerate value realization from automation investments, and maintain alignment with evolving clinical priorities.
A transparent mixed-methods research framework combining literature review, stakeholder interviews, vendor mapping, and supply chain analysis to validate automation insights
This analysis employed a mixed-methods research approach combining qualitative and quantitative evidence to ensure robust, actionable findings. The methodology began with a structured review of peer-reviewed literature, regulatory guidance documents, and technical white papers to identify technology trends, validation norms, and clinical use cases. Primary research included in-depth interviews with a cross-section of stakeholders such as laboratory directors, procurement officers, assay developers, regulatory experts, and supply chain managers to capture real-world constraints and adoption drivers.
Complementing these inputs, the study executed vendor landscape mapping to assess product architectures, recurring revenue models, and service portfolios. Supply chain analysis examined component sourcing, regional manufacturing capacity, and logistics timelines to identify vulnerabilities and mitigation tactics. Data triangulation techniques were applied to reconcile primary insights with secondary sources, and findings were validated through advisory reviews with subject-matter experts.
Ethical research practices were followed throughout, ensuring informed consent for interviews and respecting confidentiality obligations. The methodology emphasizes transparency in assumptions and traceability of evidence so that stakeholders can replicate key analyses or request tailored deep-dives on specific segments or geographies.
Concluding synthesis that connects automation-driven operational gains with strategic imperatives around integration, supply chain resilience, and clinical adoption pathways
Automation in molecular diagnostics represents both an operational imperative and a strategic opportunity for stakeholders across the diagnostic ecosystem. The transition toward modular platforms, integrated informatics, and service-oriented commercial models is reshaping how tests are developed, validated, and delivered. Laboratories that strategically adopt automation can realize improvements in throughput, consistency, and overall clinical utility, while vendors that bundle instruments with consumables and analytics can create defensible recurring revenue streams.
Yet, adoption is not uniform; regional dynamics, regulatory requirements, and tariff-induced supply chain pressures introduce complexity that demands tailored strategies. Stakeholders who proactively address integration challenges, workforce training, and supply chain resilience position themselves to capture sustainable value. Looking ahead, continued convergence of automation, genomic technologies, and data analytics will expand the range of feasible clinical applications and support more personalized diagnostic pathways.
In summary, the next phase of molecular diagnostics will be defined by platforms that deliver reliable, scalable automation, supported by interoperable software and resilient supply chains. Organizations that align technology choices with clinical priorities, regulatory realities, and commercial models will be best placed to benefit from this transformation.
Note: PDF & Excel + Online Access - 1 Year
A comprehensive orientation to the technological, operational, and commercial forces reshaping automation across molecular diagnostics laboratories and service providers
The molecular diagnostics sector is in the midst of a structural and technological transition driven by the convergence of automation, genomics, and data-centric workflows. Laboratories face mounting pressures to increase throughput, shorten turnaround times, and maintain rigorous quality standards while managing constrained budgets and an evolving regulatory environment. Concurrently, advances in sample handling, assay chemistry, and integrated informatics have created a pathway toward more repeatable, scalable laboratory operations that reduce error rates and enable broader clinical adoption of complex tests.
This report frames automation not as a single technology but as an orchestrated set of capabilities that span consumables, instrumentation, software, and services. As automation spreads beyond centralized reference labs into hospital laboratories and specialized clinical settings, stakeholders must rethink procurement, validation, and operational models. Early adopters are demonstrating measurable gains in workflow efficiency and capacity, and the ripple effects extend to payers, clinicians, and patients through faster diagnoses and more reliable results.
Given these dynamics, strategic decision-makers require a synthesis of technical, operational, and commercial perspectives. This executive summary synthesizes those perspectives to inform capital allocation, partnership strategies, and product development priorities, thereby equipping leaders to navigate the near-term opportunities and operational challenges presented by automation in molecular diagnostics.
Exploring how modular platforms, digital integration, and evolving commercial models are fundamentally transforming laboratory automation and molecular testing operations
Over the last several years, the landscape of molecular diagnostics has shifted from fragmented point solutions toward integrated automation platforms and ecosystem partnerships. Laboratories and manufacturers alike are prioritizing modularity in design to enable incremental upgrades and cross-platform compatibility, which eases integration of next-generation sequencing, PCR, and microarray workflows. This shift reflects a broader industry movement toward platform-based thinking, where instruments, consumables, and software co-evolve to deliver predictable end-to-end performance.
At the same time, digital transformation continues to accelerate, with data analysis software, integration services, and managed services gaining prominence as differentiators. Interoperability and standards-based data exchange now influence procurement decisions as strongly as instrument throughput. Decentralization of testing capacity, driven by demand for rapid results and the need to reduce sample transport times, is prompting investments in walkaway automation that can operate in lower-acuity settings.
These transformative shifts are producing new commercial models. Vendors are expanding beyond hardware sales to provide recurring-revenue offerings centered on consumables, data analytics subscriptions, and service contracts. As a result, strategic partnerships across diagnostic developers, laboratory networks, and software providers are becoming essential to scaling complex molecular tests and delivering consistent clinical value.
Assessing the supply chain recalibrations, procurement strategies, and regulatory validation pressures resulting from recent tariff changes affecting molecular diagnostics components and instruments
The introduction of new tariffs affecting components and finished diagnostics products has layered additional complexity onto an already intricate global supply chain. Increased duties on certain imported instruments and reagents elevate the total landed cost for laboratories and distributors, prompting procurement teams to reassess sourcing strategies and total cost of ownership calculations. In response, some manufacturers have accelerated dual-sourcing initiatives and re-evaluated production footprints to mitigate exposure to region-specific levies.
Consequently, buyers are navigating a trade-off between near-term price pressures and longer-term supply assurance. Procurement teams are increasingly prioritizing suppliers that can demonstrate geographic diversification, transparent cost structures, and contingency plans for capacity constraints. Tariff-driven cost increases have also sharpened focus on consumable lifecycle costs and instrument utilization, as laboratories seek to protect operating margins without compromising diagnostic quality.
Regulatory considerations further complicate the environment, as changes in material origin can trigger additional validation work and documentation. In short, the tariff landscape has prompted industry participants to strengthen supply chain resilience, renegotiate contracts with a focus on total cost and service levels, and accelerate investments in local manufacturing where feasible to reduce dependency on cross-border flows.
Understanding how product, end-user, technology, automation level, and application segmentations together dictate adoption pathways and commercial priorities across molecular diagnostics
A nuanced view of segmentation clarifies where automation investments yield the greatest operational and commercial returns. When examined by product type, consumables and reagents-spanning microarray chips, NGS library prep kits, and PCR kits-often represent the recurring revenue engine that supports platform economics, while instrument categories such as microarray systems, NGS instruments, and PCR instruments command capital investment and determine throughput capacity. Software and services, including data analysis software, integration services, and managed services, serve as force multipliers that unlock instrument value through improved data handling and laboratory workflow orchestration.
From the end-user perspective, clinical laboratories and hospital laboratories place a premium on automation solutions that reduce hands-on time and accelerate turnaround for actionable results, whereas pharmaceutical and biotechnology companies prioritize high-throughput, reproducible workflows for discovery and early-phase development. Reference laboratories and research laboratories have distinct throughput and customization requirements, influencing the balance between standardized automated solutions and flexible semi-automated or walkaway approaches.
Technology segmentation highlights divergent adoption patterns across microarrays, NGS, and PCR. PCR remains indispensable for rapid, targeted testing, whereas NGS drives complex genomic profiling and increasingly benefits from automated library preparation and integrated informatics. Microarrays occupy niches where cost-effective multiplexing is required. Automation level is also a key determinant of procurement decisions: fully automated systems enable high-throughput, standardized operations; semi-automated systems offer flexibility for variable workloads; and walkaway automation lowers the skill threshold for decentralized testing environments. Application areas such as cardiovascular disease, genetic testing, infectious disease, oncology, and women's health present distinct assay validation needs and reimbursement contexts that shape product roadmaps and commercial strategies.
Analyzing distinct regional drivers and procurement realities in the Americas, Europe Middle East & Africa, and Asia-Pacific that shape automation adoption and commercial strategies
Regional dynamics exert a strong influence on how automation strategies are prioritized and executed. In the Americas, sizable reference laboratory networks and a relatively mature reimbursement environment encourage investments in high-throughput automated platforms, while clinical and hospital laboratories seek solutions that integrate seamlessly with existing LIS and EMR infrastructure. In contrast, Europe, Middle East & Africa displays a heterogeneous landscape where regulatory harmonization efforts and national procurement practices can accelerate uptake in certain markets while creating access barriers in others.
Asia-Pacific is characterized by rapid capacity expansion, strong government-driven diagnostic initiatives, and a diverse mix of centralized and decentralized laboratory models. Local manufacturing and supplier ecosystems in parts of the region have begun to reduce lead times and provide alternative sourcing options, which impacts procurement choices elsewhere. Across all regions, data interoperability, workforce skills, and capital allocation rhythms differ materially, influencing how vendors design deployment plans and after-sales support.
Taken together, these geographic distinctions underscore the need for differentiated commercialization strategies that reflect local regulatory requirements, supply chain realities, and customer preferences. Vendors and laboratory operators that align product configurations, training programs, and financing models with regional realities will navigate adoption barriers with greater agility.
Identifying corporate strategies, partnership models, and aftermarket services that industry participants are deploying to secure competitive advantage in automated molecular diagnostics
Competitive behavior in the sector reflects an intersection of product innovation, service orientation, and ecosystem building. Leading organizations are investing in vertically integrated platforms that combine instruments, consumables, and software to lock in recurring revenue streams and to simplify customer procurement. Others are pursuing a platform-agnostic approach that emphasizes software and services, enabling interoperability across multiple instrument vendors and positioning the company as a neutral integrator for complex laboratory estates.
Partnerships and co-development arrangements with assay developers, clinical laboratories, and academic centers are increasingly common, allowing companies to accelerate time-to-validation and expand test menus. Aftermarket strategies that include managed services, training, and performance-based contracts are being used to deepen customer relationships and to smooth revenue volatility associated with capital sales. In addition, supply chain resilience and regional manufacturing footprints have become strategic differentiators as organizations seek to mitigate tariff exposure and shorten lead times.
Companies that balance technological leadership with robust service offerings and transparent commercial models tend to win long-term contracts, while those that neglect integration, data analytics, or post-sale support face adoption friction. Overall, corporate strategies that emphasize modular innovation, flexible commercial terms, and collaborative partnerships position firms to capture a widening set of automation-driven opportunities within molecular diagnostics.
Actionable strategic and operational steps for manufacturers, laboratory operators, and policymakers to accelerate scalable, resilient automation adoption across diagnostics workflows
Leaders should adopt a pragmatic approach that aligns technology investments with clinical and operational objectives. First, prioritize modular automation platforms that enable phased adoption; this reduces validation burdens and allows organizations to scale capacity in line with demand. Second, diversify supply chains and establish contingency plans that include alternate suppliers and, where feasible, regional manufacturing partners to mitigate tariff and logistics risks.
Third, invest in software and integration capabilities to maximize instrument utilization and to reduce manual touchpoints. This includes prioritizing standards-based data exchange and investing in analytics tools that translate raw data into actionable clinical insights. Fourth, engage early with regulatory and reimbursement stakeholders to define evidence generation strategies that support test adoption and favorable coverage decisions. Fifth, expand service offerings such as managed services and training programs to address workforce constraints and to improve uptime and reliability.
Finally, pursue collaborative partnerships with clinical laboratories, assay developers, and healthcare systems to co-develop and validate workflows. These partnerships accelerate real-world adoption and create feedback loops that inform product roadmaps. Implementing these recommendations will strengthen resilience, accelerate value realization from automation investments, and maintain alignment with evolving clinical priorities.
A transparent mixed-methods research framework combining literature review, stakeholder interviews, vendor mapping, and supply chain analysis to validate automation insights
This analysis employed a mixed-methods research approach combining qualitative and quantitative evidence to ensure robust, actionable findings. The methodology began with a structured review of peer-reviewed literature, regulatory guidance documents, and technical white papers to identify technology trends, validation norms, and clinical use cases. Primary research included in-depth interviews with a cross-section of stakeholders such as laboratory directors, procurement officers, assay developers, regulatory experts, and supply chain managers to capture real-world constraints and adoption drivers.
Complementing these inputs, the study executed vendor landscape mapping to assess product architectures, recurring revenue models, and service portfolios. Supply chain analysis examined component sourcing, regional manufacturing capacity, and logistics timelines to identify vulnerabilities and mitigation tactics. Data triangulation techniques were applied to reconcile primary insights with secondary sources, and findings were validated through advisory reviews with subject-matter experts.
Ethical research practices were followed throughout, ensuring informed consent for interviews and respecting confidentiality obligations. The methodology emphasizes transparency in assumptions and traceability of evidence so that stakeholders can replicate key analyses or request tailored deep-dives on specific segments or geographies.
Concluding synthesis that connects automation-driven operational gains with strategic imperatives around integration, supply chain resilience, and clinical adoption pathways
Automation in molecular diagnostics represents both an operational imperative and a strategic opportunity for stakeholders across the diagnostic ecosystem. The transition toward modular platforms, integrated informatics, and service-oriented commercial models is reshaping how tests are developed, validated, and delivered. Laboratories that strategically adopt automation can realize improvements in throughput, consistency, and overall clinical utility, while vendors that bundle instruments with consumables and analytics can create defensible recurring revenue streams.
Yet, adoption is not uniform; regional dynamics, regulatory requirements, and tariff-induced supply chain pressures introduce complexity that demands tailored strategies. Stakeholders who proactively address integration challenges, workforce training, and supply chain resilience position themselves to capture sustainable value. Looking ahead, continued convergence of automation, genomic technologies, and data analytics will expand the range of feasible clinical applications and support more personalized diagnostic pathways.
In summary, the next phase of molecular diagnostics will be defined by platforms that deliver reliable, scalable automation, supported by interoperable software and resilient supply chains. Organizations that align technology choices with clinical priorities, regulatory realities, and commercial models will be best placed to benefit from this transformation.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
195 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of high-throughput automation systems in next-generation sequencing workflows to reduce turnaround times
- 5.2. Adoption of robotic sample preparation platforms for multiplex PCR assays in decentralized diagnostic labs
- 5.3. Implementation of AI-driven data analysis pipelines for real-time interpretation of molecular diagnostic results
- 5.4. Development of modular lab-on-a-chip devices enabling automated point-of-care nucleic acid testing in remote settings
- 5.5. Standardization of automated liquid handling protocols to enhance reproducibility across multi-site molecular testing networks
- 5.6. Expansion of closed system automation combining sample extraction and qPCR to minimize contamination risk and operator error
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Automation in the Molecular Diagnostics Market, by Product Type
- 8.1. Consumables & Reagents
- 8.1.1. Microarray Chips
- 8.1.2. Ngs Library Prep Kits
- 8.1.3. Pcr Kits
- 8.2. Instruments
- 8.2.1. Microarray Systems
- 8.2.2. Ngs Instruments
- 8.2.3. Pcr Instruments
- 8.3. Software & Services
- 8.3.1. Data Analysis Software
- 8.3.2. Integration Services
- 8.3.3. Managed Services
- 9. Automation in the Molecular Diagnostics Market, by Technology
- 9.1. Microarrays
- 9.2. Ngs
- 9.3. Pcr
- 10. Automation in the Molecular Diagnostics Market, by Automation Level
- 10.1. Fully Automated Systems
- 10.2. Semi-Automated Systems
- 10.3. Walkaway Automation
- 11. Automation in the Molecular Diagnostics Market, by Application
- 11.1. Cardiovascular Diseases
- 11.2. Genetic Testing
- 11.3. Infectious Disease
- 11.4. Oncology
- 11.5. Women's Health
- 12. Automation in the Molecular Diagnostics Market, by End User
- 12.1. Clinical Laboratories
- 12.2. Hospital Laboratories
- 12.3. Pharmaceutical & Biotechnology Companies
- 12.4. Reference Laboratories
- 12.5. Research Laboratories
- 13. Automation in the Molecular Diagnostics Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Automation in the Molecular Diagnostics Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Automation in the Molecular Diagnostics Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Abbott Laboratories
- 16.3.2. Adaltis S.r.l.
- 16.3.3. altona Diagnostics GmbH
- 16.3.4. AstraGene LLC
- 16.3.5. Becton, Dickinson and Company
- 16.3.6. Biocartis NV
- 16.3.7. bioMérieux S.A.
- 16.3.8. Bruker Corporation
- 16.3.9. Danaher Corporation
- 16.3.10. DiaSorin S.p.A.
- 16.3.11. F. Hoffmann-La Roche Ltd.
- 16.3.12. Hologic, Inc.
- 16.3.13. Hudson Robotics, Inc.
- 16.3.14. Laboratory Corporation of America Holdings
- 16.3.15. MEGAROBO technologies Co., Ltd.
- 16.3.16. Olympus Corporation
- 16.3.17. Synchron Lab Automation
- 16.3.18. Sysmex Corporation
- 16.3.19. Waters Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
